Back to Search
Start Over
Data from Phase III study OASIS 3 support efficacy and long-term safety of investigational compound elinzanetant in the treatment of moderate to severe vasomotor symptoms associated with menopause
- Source :
- European Union News. September 10, 2024
- Publication Year :
- 2024
-
Abstract
- Germany: Bayer AG has issued the following press release: Bayer will present detailed results from the Phase III study OASIS 3, providing supporting efficacy data and sustained safety data over [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- European Union News
- Publication Type :
- News
- Accession number :
- edsgcl.808303179